NewsSource: EClinCloud

Officially in Effect! Key Pharmaceutical R&D Regulations to Watch Starting in September

5 min readEClinCloud Editorial Team
Modify_this_flat_vector_banner_2026-08-24T08-41-42.png

Source: EClinCloud. Author: EClinCloud.


In September, a number of pharmaceutical regulations and policies will take effect. To help industry partners stay informed of regulatory trends, EClinCloud has compiled key updates closely related to new drug R&D and clinical research for industry reference.







Modify_this_flat_vector_banner_2026-08-24T08-41-42.png
1 Revised GCP Takes Effect on September 1

The National Medical Products Administration (NMPA), National Health Commission (NHC), National Administration of Traditional Chinese Medicine (NATCM), and National Disease Control and Prevention Administration (NDCPA) jointly issued the "Announcement on Issuing the Good Clinical Practice for Drugs (2026 Revision)" (No. 50 of 2026)[1], announcing that it will take effect on September 1, 2026, while the previous 2020 edition will be repealed simultaneously.


Quick Overview of Key Changes: Added a standalone chapter on "Data Governance"; incorporated the three international concepts of quality by design, risk proportionality, and fitness for purpose into the General Provisions; clarified that the principal investigator is ultimately responsible at the trial site and the sponsor is ultimately responsible for related activities; replaced "subjects" with "trial participants"; and set out data governance requirements including metadata plus audit trails, system validation, electronic signatures, and traceability of transfers between systems.
📌 What You Can Do Now
  • Comprehensively revise quality system documents. Revise SOPs and management policies; clarify the division of responsibilities among sponsors, CROs, and trial institutions to reduce compliance risks.

  • Strengthen training and capability building. Organize training and study sessions covering all staff, and properly retain training records to support subsequent regulatory inspections.

  • Reinforce accountability awareness and mindset shift. Strengthen awareness of primary accountability among sponsors, PIs, and other responsible parties.

  • Ensure data governance and system compliance. Verify whether data modifications have complete audit trails, whether electronic signatures are compliant, whether data transfers between systems are traceable, and whether issues such as data silos or unclear data provenance exist.


2 Public Consultation on Chinese Translation of ICH E6(R3) Annex 2 (DCT / RWD) Closes September 10

On August 10, 2026, the Center for Food and Drug Inspection of NMPA (CFDI) issued the "Notice on Soliciting Public Comments on the Chinese Translation and Implementation Recommendations for Annex 2 of ICH 'E6(R3): Guideline for Good Clinical Practice (GCP)'"[2], opening a one-month public consultation.

📋 Key Takeaways

Since March 31 of this year, newly initiated drug clinical trials in China have fully applied E6(R3). On June 3, ICH formally adopted E6(R3) Annex 2. Just 2 months later, CFDI released the Chinese translation and implementation recommendations. Annex 2 is more than a translated document; it signals that DCT, pragmatic trials, and real-world data (RWD) in China are moving from an exploratory phase into a "rule-governed" phase.

📌 What you can do now
  • Review closely in light of your operational priorities. For DCT, focus on Sections 2.2–2.4 (informed consent, investigational product management, and investigator oversight); for RWD, focus on Sections 3.4–3.5 (data access and use, and data considerations).

  • Conduct an internal assessment. Map your existing SOPs, data management workflows, and vendor management systems against the requirements of Annex 2.


3 CDE seeks comments on the "Pioneer Program" (先锐计划) for cell and gene therapy products; deadline September 19
On August 19, 2026, CDE released the draft for comment on the "Pioneer Program" (先锐计划) for cell and gene therapy (CGT) products, with comments open until around September 19, 2026.[3] The program is an end-to-end review and approval support mechanism for CGT, guided by the principles of early engagement, tailored company-specific strategies, full-process guidance, and coordinated R&D and review. It admits up to 15 products per year, covering innovative drugs with novel targets or mechanisms as well as major manufacturing process optimization changes for marketed products.
📋 Key takeaways
The core value of the "Pioneer Program" lies in providing guidance across the full R&D lifecycle (from preclinical development to marketing application). As an end-to-end, front-loaded, and tailored review and approval support mechanism, it marks a shift in CGT regulation from "passive review" to "proactive guidance," entering a new stage of "front-loaded regulation". This aligns with global regulatory trends.
📌 What you can do now
  • Assess whether your products meet the eligibility criteria. Review your R&D pipeline against thresholds such as "seriously life-threatening diseases / major clinical value / major manufacturing process changes."

  • Prepare submission and communication materials in advance. Following the "one-strategy-per-company" approach, map out Type I meeting needs and supporting data at key milestones (pre-IND / pre-confirmatory trial / pre-marketing application).


4 2026 National Essential Medicines List takes effect September 1
On July 9, 2026, the National Health Commission (NHC) website published a notice on issuing the National Essential Medicines List (2026 Edition), specifying that the 2026 edition of the National Essential Medicines List will officially take effect on September 1.[4] The list adjustment will further affect clinical drug use, market access, and corporate product portfolios.
📌 Key takeaways

The Essential Medicines List has undergone its first adjustment in 8 years. Drawing the greatest attention is that innovative drugs have been included in the Essential Medicines List in batches for the first time, including 4 domestically developed Category 1 innovative drugs added at scale for the first time across key therapeutic areas such as oncology, immunology, and neurology, signaling policy support for innovative drug development. At the same time, this revision establishes real-world market sales volume and evidence-based medical evidence as prerequisite entry thresholds, underscoring the need to focus more closely on clinical value and evidence-based support, using clinical benefit and real-world performance to further validate product value.

Original document:

[1]https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20260608103856150.html

[2]https://cfdi.org.cn/cfdi/resource/news/16828.html

[3]https://www.cde.org.cn/main/news/viewInfoCommon/4a8ef5a0f7ae2e6dfca8cf3851841b1a

[4]https://www.nhc.gov.cn/yaozs/c100098/202607/0f4f2bdcfead449f8412453373522470.shtml






About EClinCloud


EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as services for scale management, linguistic validation, rater training, and data quality analysis to deliver efficient and precise digital solutions. Leveraging AI predictive models and an intelligent data platform, it dynamically evaluates and helps improve the success rate of drug clinical trials, helping shorten drug and device R&D cycles for the benefit of patients.







Article illustration



Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.